Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from ecancermedicalscience

12:38 EDT 19th June 2018 | BioPortfolio

Here are the most relevant search results for "ecancermedicalscience" found in our extensive news archives from over 250 global news sources.

More Information about ecancermedicalscience on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ecancermedicalscience for you to read. Along with our medical data and news we also list ecancermedicalscience Clinical Trials, which are updated daily. BioPortfolio also has a large database of ecancermedicalscience Companies for you to search.

Showing News Articles 1–25 of 1,100+ from ecancermedicalscience

Tuesday 19th June 2018

Sensitive new assay finds abnormalities in tumour cells that other techniques may miss

RNA-Seq is a new next-generation assay that can detect gene fusions in solid tumour cells with high accuracy and excellent reproducibility. According to a new report in The Journal of Molecular Diagnostics, the assay detected 93 percent of gene fusions...

Monday 18th June 2018

EHA 23: Quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML

A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukaemia (AML) linked to a genetic mutation called FMS-like...

Sunday 17th June 2018

Protein expression in CD138 plasma cells predicts prognosis in MM patients

Dr Misiewicz-Krzeminska speaks with ecancer at EHA 23 about the utility of proteins expressed within the plasma cells of patients with multiple myeloma who have been treated with VRD chemotherapy as prognostic factors for disease relapse and...

Treating CLL with obiutuzumab

Dr Goede speaks with ecancer at EHA 23 about the use of CD20 targeted antibody obinutuzumab compared to rituximab in combination with chlorambucil chemotherapy. He describes the 3 arms of the trial, which found the combination of obinutuzumab and...

Half of CLL patients who relapse on ibrutinib harbour BTK/PLCG mutations

Dr Scarfo speaks with ecancer at EHA 23 about a multicentre international study which finds 50% of CLL patients who have received Brutons tyrosine kinase inhibitor ibrutinib in the course of their CLL treatment who relapse harbour mutations in BTK and...

First in-human trial of AMV564 for AML

Dr Westervelt speaks with ecancer at EHA 23 about pre-clinical and early clinical results of a CD3/33 bi-specific T cell engager (BiTE) to treat AML. He outlines the data from early mouse models and human cell cultures which showed activity of the...

Onset and treatment of infantile leukaemia

Dr Roy speaks with ecancer at EHA 23 about the inciting mutations that drive infantile leukaemia. She identifies a unique foetal progenitor cell linked to the disease aetiology, and how a single mutation can start the sequence of changes leading to...

SETBP1 induces transcription of developmental genes

Dr Piazza speaks with ecancer at EHA 23 about the expression and interaction of SETBP1 in driving myeloid leukaemia. He details the network of expression, degradation and stabilisation of SETBP1 and BTRCP, which ultimately confirm that SETBP1 binds to...

Combination therapy for CLL in the CAPTIVATE trial

Dr Ghia speaks with ecancer at EHA 23 about the design and early findings of the phase II CAPTIVATE study, treating CLL patients with ibrutinib and venetoclax. He describes the sequencing of the two drugs, which are both approved as monotherapy, and...

Efficacy of novel agents in r/r T pro-lymphocytic leukaemia

Prof Staber speaks with ecancer at EHA 23 about the management TPLL, a rare blood disease, with new agents. He describes the challenges in trial design for rare diseases, and the drug screening panel used in this assessment to determine the likely...

Isatuximab in combination to treat relapsed/refractory MM

Dr Mikhael speaks with ecancer at EHA 23 about a phase Ib study of isatuximab, a CD38 targeted therapy, in combination with pomalidomide and dexamethasone to treat relapsed multiple myeloma. He outlines the dose selection, and highlights the shorter...

Final results of isatuximab in combinations to treat r/r MM

Dr Mikhael speaks with ecancer at EHA 23 about a phase Ib study of isatuximab, a CD38 targeted therapy, in combination with pomalidomide and dexamethasone to treat relapsed multiple myeloma. He outlines the dose selection, and highlights the shorter...

Venetoclax in patients with previously treated WM

Dr Castillo speaks with ecancer at EHA 23 about results from a prospective phase II study of venetoclax in previously treated Waldenström Macroglobulinemia (WM). He describes the over expression of BCL2 in these cells, and the encouraging responses of a...

Single cell profiling reveals key differences in architecture of stem and progenitor cells throughout life

Dr Roy speaks with ecancer at EHA 23 about observed changes in blood stem cells over at different stages of development, from infancy to adulthood. She describes how, starting from matched liver and bone marrow samples, changes in erythroid, myeloid and...

ICLL07 FILO study: Minimal residual disease still detectable after first line combination therapy

Prof Feugier speaks with ecancer at EHA 23 about results from a phase II trial of treating CLL with induction obinutuzumab and ibrutinib. He describes how CR with undetectable residual disease (uMRD) may be associated with a longer survival in CLL. With...

Even late progressors with high risk factors in PRIMA prognostic index are more likely to die

Dr Trněný speaks with ecancer at EHA 23 about a prognostic index for follicular lymphoma patients based on the PRIMA study. In the NiHiL project, high risk patients stratified by microglobulin levels were found to be more likely to experience...

Patient relevant outcomes and advocacy

Jan Geissler speaks with ecancer at EHA 23 about the incorporation of patient reported outcomes (PROs) alongside clinical outcomes in haematology. He discusses the essential consideration of patients priorities in treating and living with cancer, and the...

The mutational landscape of AML

Prof Bullinger speaks with ecancer at EHA 23 about the clinical implications for mutations detected in AML patients cells. He highlights key mutations including p53, IDH and Flt3 mutations, some of which are treatable with targeted agents such as...

Development of a risk stratifying prognostic index for ALL

Prof Moorman speaks with ecancer at EHA 23 about the development and validation of risk of relapse stratification equation for ALL patients. He explains how, compared to other binary risk factors, continuous data assessment can predict patients at risk...

Saturday 16th June 2018

Novel CD22 CAR-T therapy for paediatric leukaemia

Dr Pan speaks with ecancer at EHA 23 about a novel CD22 CAR-T cell for paediatric B-ALL. She outlines the remission rates and safety associated with the treatment. For more on these results, watch her presentation of data at a press session...

EHA 23: JAK inhibitors associated with aggressive lymphoma

Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas. They also speculate that screening for a preexisting B-cell clone...

Brentuximab vedotin with chemo for relapsed Hodgkin lymphoma

Dr Garcia-Sanz speaks with ecancer at EHA 23 about the results from a phase I/II trial of treating r/rHL with brentuximab vedotin, along with ESHAP chemo, to improve depth of response ahead of stem cell transplant. He describes the tolerability of the...

EHA 2018: Research, collaboration and working towards cures

Prof Sonneveld speaks with ecancer at EHA 23 about the research and advances changing care in haematology. He highlights Topics in Focus, as discussed by EHA president-elect Prof John Gribben here, a recent addition to the format of the conference which...

Lymphoma guidelines in Venezuela

Dr Torres Viera speaks with ecancer at EHA 23 about suggested guidelines for lymphoma treatment in Venezuela, and how these differ from broader global practice. She highlights the barriers to accessing PET-CT scans informing treatment reduction, late...

Educational focus on immunotherapy at EHA

EHA president-elect Prof Gribbin speaks with ecancer at EHA 23 about the development of EHA Topics in Focus, and the educational emphasis being placed on CAR-T cell immunotherapy. He discusses the reasoning behind developing Topics in Focus from the...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks